| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
|
Cancer Res
|
2008
|
6.38
|
|
2
|
Rethinking ovarian cancer: recommendations for improving outcomes.
|
Nat Rev Cancer
|
2011
|
5.28
|
|
3
|
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
|
Cancer Res
|
2006
|
2.63
|
|
4
|
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters.
|
Mol Cell
|
2006
|
2.48
|
|
5
|
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
|
Nat Med
|
2011
|
2.46
|
|
6
|
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
|
Cancer Biol Ther
|
2009
|
2.21
|
|
7
|
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
|
Cancer Res
|
2011
|
2.13
|
|
8
|
MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression.
|
Nucleic Acids Res
|
2009
|
2.03
|
|
9
|
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.
|
Cancer Res
|
2008
|
1.99
|
|
10
|
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.
|
Cancer Res
|
2004
|
1.97
|
|
11
|
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.
|
J Natl Cancer Inst
|
2010
|
1.94
|
|
12
|
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
|
Clin Cancer Res
|
2002
|
1.91
|
|
13
|
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.
|
BMC Med Genomics
|
2009
|
1.91
|
|
14
|
Epigenetic resensitization to platinum in ovarian cancer.
|
Cancer Res
|
2012
|
1.88
|
|
15
|
Alcohol alters DNA methylation patterns and inhibits neural stem cell differentiation.
|
Alcohol Clin Exp Res
|
2011
|
1.88
|
|
16
|
CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
|
Mol Endocrinol
|
2005
|
1.66
|
|
17
|
Prognostic DNA methylation biomarkers in ovarian cancer.
|
Clin Cancer Res
|
2006
|
1.53
|
|
18
|
Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation.
|
Epigenetics
|
2009
|
1.53
|
|
19
|
EGFR signaling in breast cancer: bad to the bone.
|
Semin Cell Dev Biol
|
2010
|
1.52
|
|
20
|
Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray.
|
Nucleic Acids Res
|
2004
|
1.50
|
|
21
|
Minireview: epigenetic changes in ovarian cancer.
|
Endocrinology
|
2009
|
1.49
|
|
22
|
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology.
|
BMC Genomics
|
2008
|
1.49
|
|
23
|
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.
|
Cancer Res
|
2010
|
1.45
|
|
24
|
The epigenetics of ovarian cancer drug resistance and resensitization.
|
Am J Obstet Gynecol
|
2004
|
1.41
|
|
25
|
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
|
Mol Cancer Ther
|
2005
|
1.40
|
|
26
|
Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation.
|
Cancer Res
|
2003
|
1.38
|
|
27
|
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha.
|
J Biol Chem
|
2006
|
1.35
|
|
28
|
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
|
Breast Cancer Res
|
2008
|
1.35
|
|
29
|
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
|
Cancer
|
2010
|
1.34
|
|
30
|
The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
|
Mol Endocrinol
|
2002
|
1.30
|
|
31
|
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
|
Cancer Biol Ther
|
2010
|
1.28
|
|
32
|
Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance.
|
Bioinformatics
|
2008
|
1.27
|
|
33
|
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
|
Gynecol Oncol
|
2009
|
1.26
|
|
34
|
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.
|
PLoS Genet
|
2013
|
1.24
|
|
35
|
Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
|
Cancer Res
|
2006
|
1.21
|
|
36
|
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer.
|
Clin Cancer Res
|
2005
|
1.20
|
|
37
|
Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping.
|
Genome Res
|
2010
|
1.18
|
|
38
|
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
|
Lab Invest
|
2010
|
1.17
|
|
39
|
Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells.
|
Cancer Res
|
2011
|
1.15
|
|
40
|
Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.
|
Mol Endocrinol
|
2008
|
1.14
|
|
41
|
GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response.
|
Cancer Lett
|
2011
|
1.09
|
|
42
|
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.
|
Cancer Cell
|
2013
|
1.09
|
|
43
|
Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation.
|
Mol Endocrinol
|
2004
|
1.09
|
|
44
|
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.
|
Neoplasia
|
2008
|
1.08
|
|
45
|
An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules.
|
BMC Syst Biol
|
2009
|
1.08
|
|
46
|
Androgen receptor-driven chromatin looping in prostate cancer.
|
Trends Endocrinol Metab
|
2011
|
1.07
|
|
47
|
RNA polymerase II binding patterns reveal genomic regions involved in microRNA gene regulation.
|
PLoS One
|
2010
|
1.07
|
|
48
|
Growth inhibition of ovarian tumor-initiating cells by niclosamide.
|
Mol Cancer Ther
|
2012
|
1.06
|
|
49
|
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
|
Nucleic Acids Res
|
2014
|
1.05
|
|
50
|
A new method for stranded whole transcriptome RNA-seq.
|
Methods
|
2013
|
1.05
|
|
51
|
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.
|
Epigenetics
|
2010
|
1.05
|
|
52
|
Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer.
|
Nucleic Acids Res
|
2013
|
1.03
|
|
53
|
Identification of transcription factor and microRNA binding sites in responsible to fetal alcohol syndrome.
|
BMC Genomics
|
2008
|
1.02
|
|
54
|
Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system.
|
J Comput Biol
|
2005
|
1.01
|
|
55
|
Endocrine disruptor regulation of microRNA expression in breast carcinoma cells.
|
PLoS One
|
2012
|
1.00
|
|
56
|
A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer.
|
BMC Syst Biol
|
2011
|
0.99
|
|
57
|
TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
|
Epigenetics
|
2014
|
0.99
|
|
58
|
Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
|
Epigenetics
|
2013
|
0.96
|
|
59
|
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
|
Neoplasia
|
2009
|
0.96
|
|
60
|
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.
|
Oncol Rep
|
2011
|
0.95
|
|
61
|
Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes.
|
J Biol Chem
|
2007
|
0.95
|
|
62
|
Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.
|
Carcinogenesis
|
2010
|
0.95
|
|
63
|
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
|
Cancer Res
|
2010
|
0.94
|
|
64
|
A mixture model-based discriminate analysis for identifying ordered transcription factor binding site pairs in gene promoters directly regulated by estrogen receptor-alpha.
|
Bioinformatics
|
2006
|
0.94
|
|
65
|
Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis.
|
Bioessays
|
2007
|
0.94
|
|
66
|
The activating enzyme of NEDD8 inhibits steroid receptor function.
|
Mol Endocrinol
|
2002
|
0.93
|
|
67
|
ChIP-seq defined genome-wide map of TGFβ/SMAD4 targets: implications with clinical outcome of ovarian cancer.
|
PLoS One
|
2011
|
0.92
|
|
68
|
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
|
Mol Cancer Ther
|
2008
|
0.92
|
|
69
|
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.
|
Epigenetics
|
2011
|
0.92
|
|
70
|
Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter.
|
Gynecol Oncol
|
2004
|
0.91
|
|
71
|
KR-POK interacts with p53 and represses its ability to activate transcription of p21WAF1/CDKN1A.
|
Cancer Res
|
2012
|
0.91
|
|
72
|
Multiple signaling pathways converge on beta-catenin in thyroid cancer.
|
Thyroid
|
2005
|
0.91
|
|
73
|
New anti-cancer strategies: epigenetic therapies and biomarkers.
|
Front Biosci
|
2005
|
0.91
|
|
74
|
Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.
|
Sci Rep
|
2012
|
0.90
|
|
75
|
Effects of the endocrine-disrupting chemical DDT on self-renewal and differentiation of human mesenchymal stem cells.
|
Environ Health Perspect
|
2014
|
0.90
|
|
76
|
Role of epigenomics in ovarian and endometrial cancers.
|
Epigenomics
|
2010
|
0.89
|
|
77
|
Characterization of molecular and structural determinants of selective estrogen receptor downregulators.
|
Breast Cancer Res Treat
|
2006
|
0.89
|
|
78
|
An empirical Bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer.
|
BMC Med Genomics
|
2010
|
0.88
|
|
79
|
Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus.
|
Anticancer Drugs
|
2005
|
0.88
|
|
80
|
BioVLAB-MMIA: a cloud environment for microRNA and mRNA integrated analysis (MMIA) on Amazon EC2.
|
IEEE Trans Nanobioscience
|
2012
|
0.87
|
|
81
|
Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.
|
Int J Oncol
|
2013
|
0.86
|
|
82
|
Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.
|
Exp Cell Res
|
2011
|
0.86
|
|
83
|
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
|
Autophagy
|
2011
|
0.86
|
|
84
|
Identification of candidate epigenetic biomarkers for ovarian cancer detection.
|
Oncol Rep
|
2009
|
0.85
|
|
85
|
Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients.
|
Hum Mol Genet
|
2013
|
0.85
|
|
86
|
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
|
Cancer Biol Ther
|
2010
|
0.85
|
|
87
|
An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells.
|
BMC Genomics
|
2012
|
0.84
|
|
88
|
MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
|
PLoS One
|
2013
|
0.84
|
|
89
|
Epigenetic targeting therapies to overcome chemotherapy resistance.
|
Adv Exp Med Biol
|
2013
|
0.84
|
|
90
|
Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells.
|
Bioinformatics
|
2008
|
0.84
|
|
91
|
Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
|
Mol Cancer Res
|
2012
|
0.83
|
|
92
|
Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.
|
Bioconjug Chem
|
2010
|
0.81
|
|
93
|
A modulator based regulatory network for ERα signaling pathway.
|
BMC Genomics
|
2012
|
0.81
|
|
94
|
The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells.
|
Environ Health Perspect
|
2012
|
0.81
|
|
95
|
Stranded Whole Transcriptome RNA-Seq for All RNA Types.
|
Curr Protoc Hum Genet
|
2015
|
0.81
|
|
96
|
Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats.
|
Anticancer Drugs
|
2002
|
0.81
|
|
97
|
The influence of cis-regulatory elements on DNA methylation fidelity.
|
PLoS One
|
2012
|
0.81
|
|
98
|
Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.
|
J Urol
|
2011
|
0.80
|
|
99
|
Comparative analysis using K-mer and K-flank patterns provides evidence for CpG island sequence evolution in mammalian genomes.
|
Nucleic Acids Res
|
2013
|
0.80
|
|
100
|
SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
|
Mol Carcinog
|
2013
|
0.80
|
|
101
|
Striatin-3 gamma inhibits estrogen receptor activity by recruiting a protein phosphatase.
|
J Mol Endocrinol
|
2008
|
0.80
|
|
102
|
microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
|
Mol Cancer
|
2014
|
0.79
|
|
103
|
A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells.
|
Cancer Biol Ther
|
2012
|
0.78
|
|
104
|
What will it take to obtain DNA methylation markers for early cervical cancer detection?
|
Gynecol Oncol
|
2009
|
0.78
|
|
105
|
Molecular determinants of chemotherapy resistance in ovarian cancer.
|
Pharmacogenomics
|
2015
|
0.77
|
|
106
|
The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer.
|
Cancer Biomark
|
2011
|
0.77
|
|
107
|
Global DNA methylation profiling technologies and the ovarian cancer methylome.
|
Methods Mol Biol
|
2015
|
0.76
|
|
108
|
Genome-wide analysis and modeling of DNA methylation susceptibility in 30 breast cancer cell lines by using CpG flanking sequences.
|
J Bioinform Comput Biol
|
2013
|
0.76
|
|
109
|
3D culture adds an extra dimension to targeted epigenetic therapies.
|
Cell Cycle
|
2013
|
0.75
|
|
110
|
Empirical bayes model comparisons for differential methylation analysis.
|
Comp Funct Genomics
|
2012
|
0.75
|